GCM
PSTV

Goldman Capital Management’s Plus Therapeutics PSTV Stock Holding History

Goldman Capital Management’s Portfolio PSTV Stock Details PSTV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Hold
0
– -$204K – 34
2014
Q4 		– Sell
-1
Closed -$1.36M – 31
2014
Q3 		$1.09M Buy
+1
New +$4.54M 0.55% 21
2014
Q2 		– Hold
0
– – – 17
2014
Q1 		– Hold
0
– – – 24
2013
Q4 		– Hold
0
– – – 20
2013
Q3 		– Hold
0
– – – 22
2013
Q2 		– Hold
0
– – – 24

Other funds holding PSTV

BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PCMI
Princeton Capital Management Inc Princeton, New Jersey $198M AUM 28.98% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Goldman Capital Management's PSTV Position: Q1 2015 in Review

Goldman Capital Management held its Plus Therapeutics (PSTV) position steady in Q1 2015 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #34.

Goldman Capital Management first reported a position in PSTV in Q3 2014 and has held it in 1 quarter since. The position peaked at $1.09M in Q3 2014. 3 funds tracked by Wall St. Rank hold PSTV as of Q1 2015.

  • Goldman Capital Management held 0 shares of Plus Therapeutics worth $0 as of Q1 2015.
  • Goldman Capital Management left its Plus Therapeutics share count unchanged in Q1 2015.
  • Plus Therapeutics made up ﹤0.01% of Goldman Capital Management's portfolio in Q1 2015, its #34 holding.
  • Goldman Capital Management first reported a position in Plus Therapeutics in Q3 2014 and has held it in 1 quarter since.
  • Goldman Capital Management's Plus Therapeutics position peaked at $1.09M in Q3 2014.
  • 3 funds tracked by Wall St. Rank held Plus Therapeutics as of Q1 2015.

Based on Goldman Capital Management's 13F filing for Q1 2015, filed 29 Apr 2015.